Armata Pharmaceuticals, Inc. (ARMP) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Armata Pharmaceuticals is a late clinical-stage biotechnology company developing bacteriophage therapeutics for antibiotic-resistant bacterial infections. The company operates as a single segment focused on two primary candidates: AP-PA02 (for Pseudomonas aeruginosa) and AP-SA02 (for Staphylococcus aureus bacteremia).
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Grant and Award Revenue | $0.8 million | $0.5 million |
| Total Operating Expenses | $9.6 million | $8.7 million |
| Operating Loss | $(8.8) million | $(8.2) million |
| Net Loss | $(115.3) million | $(6.5) million |
| Net Loss Per Share (Basic/Diluted) | $(3.16) | $(0.18) / $(0.20) |
| Cash and Cash Equivalents | $4.8 million | $11.7 million |
| Restricted Cash | $4.1 million | $5.4 million |
| Total Debt (Convertible + Term) | $342.9 million | $256.9 million |
| Accumulated Deficit | $(616.9) million | $(334.3) million |
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss increased significantly to $115.3 million from $6.5 million in Q1 2025. This was driven primarily by a $101.1 million non-cash loss due to the change in fair value of the Convertible Loan, compared to a $5.2 million gain in the prior year.
- Debt Obligations: The carrying value of the Convertible Loan increased from $153.9 million to $254.9 million due to fair value adjustments. Total term debt decreased slightly due to amortization but remains high.
- Liquidity: Cash and cash equivalents declined by approximately $3.9 million to $4.8 million. The company reported a net cash outflow from operating activities of $5.8 million.
- Operating Expenses: R&D expenses rose 12.6% to $6.1 million, primarily due to increased lab supplies and engineering runs related to FDA End-of-Phase 2 meeting preparations.
Guidance, Outlook, and Risks
- Going Concern Warning: Management explicitly states that existing cash ($4.8 million) is insufficient to fund operations for the next 12 months. This raises substantial doubt about the company's ability to continue as a going concern without additional financing.
- Recent Financing:
- May 2026 Loan: Entered into a new $25.0 million secured term loan with Innoviva Sub on May 12, 2026 (14% interest, matures Jan 2029).
- Debt Amendments: In January 2026, extended maturity dates of existing credit agreements to June 2027 and warrants to 2031. This was accounted for as a Troubled Debt Restructuring (TDR).
- Sales Agreement: Maintains an "At-the-Market" sales agreement allowing up to $100 million in equity sales.
- Clinical Progress:
- AP-SA02: Received FDA Qualified Infectious Disease Product (QIDP) designation and Fast Track status. FDA confirmed support for advancing to a Phase 3 superiority study, expected to initiate in H2 2026.
- AP-PA02: Completed Phase 2 "Tailwind" study in non-CF bronchiectasis; exploring Phase 3 contingent on funding.
- Risks: High reliance on debt financing with significant interest rates (14% on term loans); potential dilution from equity raises; uncertainty of securing additional capital on favorable terms.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the new $25 million May 2026 loan against the stated 12-month funding gap.
- Debt Covenants: Review the specific financial covenants and "material adverse effect" clauses in the amended credit agreements with Innoviva.
- Convertible Loan Valuation: Assess the sensitivity of the $254.9 million Convertible Loan fair value to future stock price fluctuations, as this drives significant non-cash volatility in net income.
- Phase 3 Funding: Confirm the specific capital requirements and timeline for the AP-SA02 Phase 3 trial initiation in late 2026.
- Grant Revenue: Monitor the drawdown schedule of the $26.2 million MTEC/DoD award to ensure continued revenue recognition.